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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the efficacy and safety of metformin in treating women with endometrial hyperplasia.
B A C K G R O U N D
Description of the condition
Endometrial hyperplasia is a precancerous endometrial lesion that
commonly presents with abnormal uterine bleeding. It is thought
to be due to unopposed, prolonged exposure of the endometrium
to oestrogen and, if managed expectantly, can progress to en-
dometrial carcinoma, although the condition may resolve sponta-
neously. It is diagnosed histologically and can be subsequently cat-
egorised into four subtypes; simple, simple with atypia, complex
and complex with atypia (Kurman 1985). Risk of progression to
endometrial carcinoma is dependent on the type of endometrial
hyperplasia, and progression rates vary widely across the literature.
This discrepancy is likely due, in part, to the fact that many cases
of endometrial hyperplasia, especially when atypia is present, are
managed pre-emptively with a hysterectomy. However, atypia is
thought to be a strong risk factor for progression to adenocarci-
noma (Kurman 1985). Progression rates have been reported as less
than 5% for non-atypical hyperplasia but 28% for atypical hyper-
plasia cumulatively over 20 years. This difference in progression
risk has also been seen at interval-specific time points of four years,
nine years and 20 years post diagnosis (Lacey 2010). Risk factors
for endometrial hyperplasia are, predictably, very similar to those
for endometrial carcinoma and include obesity, diabetes mellitus,
nulliparity, tamoxifen use, oestrogen therapy and polycystic ovar-
ian syndrome (PCOS) (Torres 2012).
Polycystic ovarian syndrome is a metabolically driven gynaecolog-
ical disorder thought to affect 10% of women of child-bearing
age (Chang 2002). A diagnosis of PCOS must fulfil the widely
accepted Rotterdam criteria of two or more of the following in
the absence of another cause of chronic anovulation: hyperandro-
genism (clinical or biochemical), chronic oligo/anovulation and
polycystic ovaries apparent on ultrasound (ESHRE/ASRM2004).
Prevalence of endometrial hyperplasia inwomenwith PCOSvaries
greatly in the literature - between 1% and 48.8% (Cheung 2001;
Holm 2012; Rudnicka 2009; Tingthanatikul 2006) - but risk of
endometrial carcinoma is well founded, as women with PCOS
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possess a three-fold increased risk of developing endometrial car-
cinoma when compared with the non-PCOS population (Haoula
2012).
The aim of endometrial hyperplasia treatment, whether or not
PCOS is a co-morbidity, is to control abnormal vaginal bleed-
ing while minimising risk of progression to endometrial carci-
noma. Historically, endometrial hyperplasia without atypia has
been medically treated with oral progestogens (alone or in com-
bination with oestrogen in PCOS) or intrauterine progestogens,
inhibiting oestrogen-driven cell growth and inducing withdrawal
bleeds (Yang 2011). This treatment provides the benefit of pre-
serving fertility but is associated with side effects - in the short
term, headaches, mood changes, acne or breast tenderness, and
over the longer term, risk of a thromboembolic event or breast
cancer. These longer-term side effects can be mitigated by edu-
cating women on the symptoms of thromboembolic events and
by ensuring that they attend regular breast cancer screening pro-
grammes. This approach has the effect of potentially hindering
compliance, consequently producing a relatively high relapse rate.
In one study, 30.3% and 13.7% of women treated with oral pro-
gestogens and intrauterine levonorgestrel, respectively, had relapse
of their endometrial hyperplasia (Gallos 2013). In women with
atypia and in those who are resistant to progestogens, surgical hys-
terectomy is the treatment of choice.
Description of the intervention
Metformin, a biguanide that acts as an insulin sensitiser, is the
most commonly used oral hypoglycaemic agent in type 2 diabetes
mellitus. It acts to inhibit hepatic gluconeogenesis, decreasing liver
glucose production and thereby decreasing levels of circulating
glucose and insulin.
Metformin is also prescribed for women with PCOS to induce
weight loss and improve menstrual regularity, both as monother-
apy and in combination with a progestogen. It is frequently used
to treat ovulation dysfunction in women with PCOS when they
have shown resistance to treatment with clomiphene. Despite
widespread use of metformin in women with PCOS, no definitive
improvement in clinical or biochemical features has been shown
on systematic review when metformin is compared with the oral
contraceptive pill (Costello 2007). It has an established side ef-
fect profile, including nausea and vomiting, diarrhoea, abdominal
pain and changes in taste, as well as rarer or less publicised effects
including lactic acidosis or decreased B12 absorption, possibly
leading to anaemia and potentially irreversible neuronal damage if
left unmonitored and uncorrected for prolonged periods (de Jager
2010).
How the intervention might work
Hyperinsulinaemia secondary to insulin resistance is thought to
exhibit a mitogenic effect, inducing cell division via mitosis - a risk
factor for hyperplasia - and, ultimately, carcinoma development.
This effect is likely due to its activity at the insulin-like growth fac-
tor-1 receptor, promoting proliferation and angiogenesis, which
can be demonstrated by the positive correlation between diabetes
and breast and gynaecological cancers (Vrachnis 2016). Insulin-
mediating effects of metformin, then, show evidence of reduc-
ing incidence and improving survival among these malignancies,
although the evidence is mixed (Chlebowski 2012; Nevadunsky
2014). The link between insulin resistance and cell proliferation
offers an intriguing potential therapeutic target to reverse hyper-
plasia and prevent endometrial carcinoma. Some early trials have
corroborated this link, showing efficacy of metformin in inducing
endometrial atrophy in benign endometrial proliferative disorders;
one reported atrophy and therefore reversal of endometrial hyper-
plasia in 96% of women treated with metformin (Tabrizi 2014).
Other proposed mechanisms of the anti-cancer properties of met-
formin include its direct effects on cell signalling pathways, includ-
ing inhibition of the mammalian target of rapamycin (mTOR)
and inhibition of mitogen-activated protein kinase (MAPK) and
Akt activity. These pathways are involved in cell proliferation and
therefore play a key role in both hyperplasia and cancerous lesions
in any tissue. As metformin inhibits these pathways, cell prolif-
eration will be hindered, reducing the chance of development of
cancerous lesions (Alimova 2009; Ben 2011).
Why it is important to do this review
Currentmedical therapy for endometrial hyperplasia involvesmul-
tiple side effects and leaves the risk of recurrence. Therefore, a
systematic review of a novel, alternative therapy is needed to col-
late the evidence to date and guide future human trials. Risk of
progression from endometrial hyperplasia to carcinoma is signifi-
cant; up to 40% of women suffering from endometrial hyperplasia
with atypia go on to develop carcinoma, the most common fatal
gynaecological malignancy (Kim 2013). This rate is expected to
increase by up to 100% globally over the next 20 years (Dowling
2011). The biguanide insulin sensitiser metformin has been linked
to reversal of endometrial hyperplasia (Tabrizi 2014) and, if it can
be used in this way, may contribute to decreasing the prevalence
of endometrial carcinoma without leading to the fertility conse-
quences of current therapies. Metformin is also used as an alter-
native therapy in women with PCOS, among whom risk of en-
dometrial hyperplasia is increased. However, the mode of action,
efficacy and safety of metformin remain unclear. This review may
help to clarify its role in the treatment of women with this disease.
O B J E C T I V E S
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To determine the efficacy and safety of metformin in treating
women with endometrial hyperplasia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
The reviewwill consider only randomised controlled trials (RCTs),
both published and unpublished, as eligible for inclusion. We will
include cross-over trials, but we will use in the analysis only data
from the first phase, as cross-over is not a valid study design for
the purposes of this review.
Types of participants
Wewill select women who have histologically confirmed endome-
trial hyperplasia of any type as the study population of the review.
Types of interventions
We will include trials of metformin compared with placebo or
no treatment, conventional medical treatment (typically progesto-
gens, e.g. oral or intrauterine) or any other active intervention. We
will include trials that provide co-interventions (e.g. metformin
plus progesterone vs progesterone) but will analyse these studies
separately.
Types of outcome measures
Primary outcomes
• Regression of endometrial hyperplasia histology (with or
without atypia) towards normal histology.
Secondary outcomes
• Recurrence of endometrial hyperplasia.
• Progression of endometrial hyperplasia to endometrial
cancer.
• Hysterectomy rate.
• Abnormal uterine bleeding.
• Health-related quality of life, as reported in the included
study.
• Adverse effects during treatment, as reported in the
included study.
We will report outcomes measured after short-term treatment (up
to six months post treatment), medium-term treatment (six to 12
months post treatment) and long-term treatment (more than 12
months post treatment).
Search methods for identification of studies
We will search for all published and unpublished RCTs of met-
formin for endometrial hyperplasia without language restriction.
Review authors will liaise with the Cochrane Gynacology and
Fertility Group Trials Search Co-ordinator when conducting the
search.
Electronic searches
In accordance with guidance from the Cochrane Gynacology and
Fertility Group, we will create search strategies for the following
electronic databases to identify all relevant RCTs.
• Cochrane Gynaecology and Fertility Specialised Register
(inception to present) (Appendix 1).
• Cochrane Central Register of Controlled Trials (Ovid
CENTRAL) (inception to present) (Appendix 2).
• Ovid MEDLINE (inception to present) (Appendix 3).
• Ovid EMBASE (inception to present) (Appendix 4).
• EBSCO Cumulative Index to Nursing and Allied Health
Literaure (CINAHL) (inception to present) (Appendix 5).
• PubMed (inception to present) (Appendix 6).
• Google Scholar (inception to present) (Appendix 7).
We will perform a further search to identify ongoing or unpub-
lished trials related to the review.
• ClinicalTrials.gov (inception to present) (Appendix 8).
• World Health Organization International Trials Registry
Platform search portal (inception to present) (Appendix 9).
• OpenGrey (inception to present) (Appendix 10).
• Latin American Caribbean Health Sciences Literature
(LILACS) (inception to present) (Appendix 11).
We will present a list of search strings in the appendices and will
email the contact persons of all unpublished trials identified to
assess these studies for potential inclusion.
Searching other resources
To identify additional trials, we will handsearch the bibliographies
of all included studies, as well as any reviews on the topic. We
will also handsearch the European Society of Human Reproduc-
tion and Embryology (ESHRE) 2015 and the American Society
for ReproductiveMedicine (ASRM) 2015 conference abstracts for
relevant presentations. Previous abstracts from these conferences
are already incorporated into the Cochrane Gynaecology and Fer-
tility Specialised Register.
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Data collection and analysis
Selection of studies
We will add to a reference manager (Covidence) the titles and
abstracts of all studies retrieved by electronic searches and will
remove duplicates. Two review authors (NC, TO, JS, HS) will
independently review each entry and will assess titles and abstracts
for potential inclusion in the review. We will seek full-text reports
for potentially relevant studies. Again, two review authors (NC,
TO, JS, HS) will independently assess each full-text report against
the inclusion criteria andwill document a justification for rejection
of each study. Review authors will resolve disagreements between
them regarding trial suitability by discussion or by consultation
with a third review author. We will screen studies for duplicate
publication by comparing study author names, locations, dates
and durations. When uncertainty about study methods or the
possibility of duplicate studies arises, we will contact the authors
of relevant papers.
We will construct a flow chart to illustrate selection of studies for
inclusion in this review according to PRISMA (Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses) guidelines
(Moher 2009).
Data extraction and management
Two review authors will independently extract data using a data
extraction form that is based on the ’Checklist of items to consider
in data collection or data extraction’ provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
During study selection, if we find a study that has been published
multiple times, we will extract and collate the data into a single
file. We will treat such studies as a single unit of interest for the
review and will attribute multiple references to the single file.
When necessary, we will liaise with study authors to obtain addi-
tional data on their methods and/or results.
Assessment of risk of bias in included studies
Two review authors (from NC, TO, HS or JS) will independently
assess each included study for risk of bias by using the Cochrane
’Risk of bias’ assessment tool, as described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
will categorise bias in the following manner.
• Selection bias (random sequence generation and allocation
concealment).
• Performance bias (blinding of participants and personnel).
• Detection bias (blinding of outcome assessments).
• Attrition bias (incomplete outcome data).
• Reporting bias (selective reporting).
• Other bias (other sources of bias).
We will classify risk of bias as ’low’, ’high’ or ’unclear’ for all do-
mains mentioned above by using the ’Criteria for judging risk of
bias’ in the ‘Risk of bias’ assessment tool (Higgins 2011). We will
resolve disagreements by discussion andwhen necessary by consul-
tation with a third review author. We will fully justify judgements
made and will include this information in the ’Risk of bias’ table.
We will account for findings of this assessment when we interpret
findings of the review, as when performing the sensitivity analysis.
We will report the level of risk chosen and evidence used to make
that judgement, for example, quotes from the text, in a ’Charac-
teristics of included studies’ table. To minimise bias in selective
reporting of trial outcomes, when possible, we will compare pub-
lished protocols versus methods described in the final study.
Measures of treatment effect
For dichotomous data (e.g. regression of endometrial hyperpla-
sia, progression to endometrial carcinoma), we will calculate the
Mantel-Haenszel odds ratio (OR) from the numbers of events in
control and intervention groups.
For continuous data, we will use means, standard deviations and
mean differences (MDs). We will treat ordinal data, such as side
effect severity scoring systems or health-related quality of life ques-
tionnaires, as continuous data for purposes of analysis. When dif-
ferent scales are used to report similar outcomes (e.g. change in
endometrial thickness), we will calculate the standardised mean
difference (SMD). We will express the SMD effect as small (0.2
to < 0.5), medium (0.5 to < 0.8) or large (≥ 0.8).
We will provide 95% confidence intervals (CIs) for all outcomes.
When ORs and MDs cannot be derived from the data, we will
perform an alternative statistical analysis of included studies when
possible. We will report the values produced by analysis in full,
along with the direction and magnitude of effect of the interven-
tion, and whether or not findings are statistically significant.
Unit of analysis issues
We will perform the primary analysis per woman. When a valid
analysis is not possible (e.g. ’per cycle’ data), we will briefly sum-
marise the data but will not include them in the meta-analysis. We
will include in the analysis only first-phase data from cross-over
trials.
Dealing with missing data
Wewill analyse only available data.When contacting study authors
for missing information, we will send a first reminder email 14
days and a second reminder email 21 days after the initial email.
Should we determine that data are missing, we will address the
potential impact of this fact in theDiscussion section of the review.
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Assessment of heterogeneity
We will consider whether clinical and methodological character-
istics of included studies are sufficiently similar for meta-analysis
to provide a clinically meaningful summary. We will assess statis-
tical heterogeneity by using the measure of I2. We will consider I
2 greater than 50% to indicate substantial heterogeneity (Higgins
2003; Higgins 2011).
Assessment of reporting biases
Reporting bias is a potential issue for all reviews. We will aim to
identify and minimise reporting bias in our analysis by creating
a comprehensive search strategy and utilising a multitude of elec-
tronic databases, including those that record unpublished work
and work prepared in languages other than English. This should
ensure that we maximise the yield of eligible studies included in
the review and identify cases of data duplication.
If we include 10 or more studies in a single analysis, we will use
a funnel plot to explore the possibility of small-study effects (i.e.
the tendency for estimates of the intervention effect to be more
beneficial in smaller studies).
Data synthesis
If identified studies are sufficiently similar, we will combine the
data using a fixed-effect model for the following comparisons.
• Metformin versus placebo or no treatment.
• Metformin versus progestogens.
• Metformin versus other active intervention.
• Metformin plus co-intervention versus co-intervention
alone.
We will stratify analyses by dose of metformin (high, moderate,
low).
We will graphically display results of these meta-analyses, with
increasing odds (regardless of whether the outcome is beneficial)
demonstrated by a marker right of the centre-line and decreasing
odds by a marker left of the centre-line.
Subgroup analysis and investigation of heterogeneity
When data are available, we will conduct subgroup analyses to
determine separate evidence within the following subgroups.
• Women with PCOS.
• Women with atypical endometrial hyperplasia.
Should pooled data demonstrate substantial heterogeneity (>
50%), we will consider additional subgroup analyses (e.g. by
dose or route of metformin) and/or sensitivity analyses. We will
acknowledge the degree of heterogeneity when interpreting the
meta-analysis.
Sensitivity analysis
We will conduct a sensitivity analysis for the primary outcome
to determine whether the conclusions are robust to our choice of
methods with regards to study eligibility and analysis. Through
this sensitivity analysis, we will explore whether the review con-
clusions would have been different if:
• all studies with high risk of bias in one or more domains
were excluded from the analysis;
• a random-effects model had been implemented; or
• the effect estimate had been expressed as risk ratio (RR)
rather than OR.
Overall quality of the body of evidence: Summary of
findings table
We will prepare a ’Summary of findings’ table by using GRADE-
pro Guideline Development Tool software. In this table, we will
present a concise overview of the quality of available evidence per-
taining to the review outcomes (regression of endometrial hyper-
plasia towards normal histology, recurrence of endometrial hyper-
plasia, progression of endometrial hyperplasia to endometrial can-
cer, hysterectomy rate, abnormal uterine bleeding, health-related
quality of life, as reported in included studies and adverse effects
during treatment as reported in included studies). In accordance
with GRADE (Grades of Recommendation, Assessment, Devel-
opment and Evaluation Working Group) criteria (study limita-
tions, consistency of effect, imprecision, indirectness and publica-
tion bias), we will rate the quality of the evidence as ’high’, ’mod-
erate’, ’low’ or ’very low’. We will document the justification for
each grade awarded and will incorporate the overall grade into the
final conclusion drawn from the results.
A C K N OW L E D G E M E N T S
We would like to thank the Cochrane Gynaecology and Fertility
Group (formerly theMenstrual Disorders and Subfertitlty Group)
in Auckland for help and support provided, especially Marian
Showell for assistance with the search protocols, and HelenNagels
as the Managing Editor.
5Metformin for endometrial hyperplasia (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Alimova 2009
Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind
SE, et al. Metformin inhibits breast cancer cell growth,
colony formation and induces cell cycle arrest in vitro. Cell
Cycle (Georgetown, Tex) 2009;8(6):909–15. [PUBMED:
19221498]
Ben 2011
Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le
Marchand-Brustel Y, Auberger P, et al. Metformin,
independent of AMPK, induces mTOR inhibition and cell-
cycle arrest through REDD1. Cancer Research 2011;71(13):
4366–72. [PUBMED: 21540236]
Chang 2002
Chang RJ, Heindel JJ, Dunaif A. Polcystic ovarian
syndrome. Polycystic ovarian syndrome. New York: Marcel
Dekker Inc, 2002.
Cheung 2001
Cheung AP. Ultrasound and menstrual history in predicting
endometrial hyperplasia in polycystic ovary syndrome.
Obstetrics and Gynecology 2001;98(2):325–31. [PUBMED:
11506853]
Chlebowski 2012
Chlebowski RT, McTiernan A, Wactawski-Wende J,
Manson JE, Aragaki AK, Rohan T, et al. Diabetes,
metformin, and breast cancer in postmenopausal women.
Journal of Clinical Oncology 2012;30(23):2844–52.
[PUBMED: 22689798]
Costello 2007
Costello M, Shrestha B, Eden J, Sjoblom P, Johnson
N. Insulin-sensitising drugs versus the combined oral
contraceptive pill for hirsutism, acne and risk of diabetes,
cardiovascular disease, and endometrial cancer in polycystic
ovary syndrome. The Cochrane Database of Systematic
Reviews 2007;1(1):CD005552. [PUBMED: 17253562]
de Jager 2010
de Jager J, Kooy A, Lehert P, Wulffele MG, van der Kolk
J, Bets D, et al. Long term treatment with metformin in
patients with type 2 diabetes and risk of vitamin B-12
deficiency: randomised placebo controlled trial. BMJ
(Clinical Research ed) 2010;340:c2181. [PUBMED:
20488910]
Dowling 2011
Dowling RJ, Goodwin PJ, Stambolic V. Understanding
the benefit of metformin use in cancer treatment. BMC
Medicine 2011;9:33. [PUBMED: 21470407]
ESHRE/ASRM 2004
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group. Revised 2003 consensus on diagnostic
criteria and long-term health risks related to polycystic
ovary syndrome. Fertility and Sterility 2004;81(1):19–25.
[PUBMED: 14711538]
Gallos 2013
Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta
JK. Relapse of endometrial hyperplasia after conservative
treatment: a cohort study with long-term follow-up.
Human Reproduction (Oxford, England) 2013;28(5):
1231–6. [PUBMED: 23466671]
Haoula 2012
Haoula Z, Salman M, Atiomo W. Evaluating the association
between endometrial cancer and polycystic ovary syndrome.
Human Reproduction (Oxford, England) 2012;27(5):
1327–31. [PUBMED: 22367984]
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(557):60.
Higgins 2011
Higgins JPT, Green S. Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 [updated March
2011]. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. The
Cochrane Collaboration, 2011.
Holm 2012
Holm NS, Glintborg D, Andersen MS, Schledermann
D, Ravn P. The prevalence of endometrial hyperplasia
and endometrial cancer in women with polycystic
ovary syndrome or hyperandrogenism. Acta Obstetricia
et Gynecologica Scandinavica 2012;91(10):1173–6.
[PUBMED: 22583042]
Kim 2013
Kim JJ, Kurita T, Bulun SE. Progesterone action in
endometrial cancer, endometriosis, uterine fibroids, and
breast cancer. Endocrine Reviews 2013;34(1):130–62.
[PUBMED: 23303565]
Kurman 1985
Kurman RJ, Kaminski PF, Norris HJ. The behavior of
endometrial hyperplasia. A long-term study of “untreated”
hyperplasia in 170 patients. Cancer 1985;56(2):403–12.
[PUBMED: 4005805]
Lacey 2010
Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe
OB, Duggan MA, et al. Absolute risk of endometrial
carcinoma during 20-year follow-up among women with
endometrial hyperplasia. Journal of Clinical Oncology
2010;28:788–92. [DOI: 10.1200/JCO.2009.24.1315;
PUBMED: 20065186]
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman D, The PRISMA
Group. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. PLoS Medicine
2009;6(7):e1000097.
Nevadunsky 2014
Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A,
Kaur G, Frimer M, et al. Metformin use and endometrial
6Metformin for endometrial hyperplasia (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
cancer survival. Gynecologic Oncology 2014;132(1):236–40.
[PUBMED: 24189334]
Rudnicka 2009
Rudnicka E, Wierzba W, Radowicki S. Evaluation
of endometrial histologic morphology in patients
with polycystic ovary syndrome [Ocena obrazow
morfologicznych endometrium u pacjentek z zespolem
policystycznych jajnikow.]. Ginekologia Polska 2009;80(2):
103–6. [PUBMED: 19338206]
Tabrizi 2014
Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M,
Bidadi S. Antiproliferative effects of metformin on the
endometrium - a clinical trial. Asian Pacific Organisation for
Cancer Prevention 2014;15(23):10067–70.
Tingthanatikul 2006
Tingthanatikul Y, Choktanasiri W, Rochanawutanon
M, Weerakeit S. Prevalence and clinical predictors of
endometrial hyperplasia in anovulatory women presenting
with amenorrhea. Gynecological Endocrinology 2006;22(2):
101–5. [PUBMED: 16603436]
Torres 2012
Torres ML, Weaver AL, Kumar S, Uccella S, Famuyide AO,
Cliby WA, et al. Risk factors for developing endometrial
cancer after benign endometrial sampling. Obstetrics
and Gynecology 2012;120(5):998–1004. [PUBMED:
23090515]
Vrachnis 2016
Vrachnis N, Lavazzo C, Iliodromiti Z, Sifakis S, Alexandrou
A, Siristatidis C, et al. Diabetes mellitus and gynecologic
cancer: molecular mechanisms, epidemiological, clinical
and prognostic perspectives. Archives of Gynaecology and
Obstetrics 2016;293(2):239–46.
Yang 2011
Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate
endometrial tumor suppressor. Trends in Endocrinology and
Metabolism 2011;22(4):145–52. [PUBMED: 21353793]
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. Gynaecology and Fertility Specialised Register search strategy
Keywords CONTAINS “endometrial hyperplasia” or “endometrial proliferation” or “endometrial thickness” or “proliferation” or “hy-
perplasia” or Title CONTAINS “endometrial hyperplasia” or “endometrial proliferation” or “endometrial thickness” or “proliferation”
or “hyperplasia”
AND
Keywords CONTAINS “metformin” or “glucophage” or Title CONTAINS “metformin” or “glucophage”
Appendix 2. CENTRAL search strategy
1. exp Endometrial Hyperplasia/
2. (endometri$ adj5 hyperplas$).tw.
3. (endometri$ adj3 proliferat$).tw.
4. or/1-3
5. exp Metformin/
6. metformin.tw.
7. glucophage.tw.
8. (dimethylbiguanidine or dimethylguanylguanidine).tw.
9. (dimethylbiguanidium or glucovance).tw.
10. or/5-9
11. 4 and 10
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Appendix 3. MEDLINE search strategy
1. exp Endometrial Hyperplasia/
2. (endometri$ adj5 hyperplas$).tw.
3. (endometri$ adj3 proliferat$).tw.
4. or/1-3
5. exp Metformin/
6. metformin.tw.
7. glucophage.tw.
8. (dimethylbiguanidine or dimethylguanylguanidine).tw.
9. (dimethylbiguanidium or glucovance).tw.
10. or/5-9
11. 4 and 10
12. randomized controlled trial.pt.
13. controlled clinical trial.pt.
14. randomized.ab.
15. randomised.ab.
16. placebo.tw.
17. clinical trials as topic.sh.
18. randomly.ab.
19. trial.ti.
20. (crossover or cross-over or cross over).tw.
21. or/12-20
22. exp animals/ not humans.sh.
23. 21 not 22
24. 11 and 23
Appendix 4. EMBASE search strategy
1. exp endometrium hyperplasia/
2. (endometri$ adj5 hyperplas$).tw.
3. (endometri$ adj3 proliferat$).tw.
4. or/1-3
5. exp metformin/
6. metformin.tw.
7. glucophage.tw.
8. (dimethylbiguanidine or dimethylguanylguanidine).tw.
9. (dimethylbiguanidium or glucovance).tw.
10. or/5-9
11. 4 and 10
12. Clinical Trial/
13. Randomized Controlled Trial/
14. exp randomization/
15. Single Blind Procedure/
16. Double Blind Procedure/
17. Crossover Procedure/
18. Placebo/
19. Randomi?ed controlled trial$.tw.
20. Rct.tw.
21. random allocation.tw.
22. randomly.tw.
23. randomly allocated.tw.
24. allocated randomly.tw.
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25. (allocated adj2 random).tw.
26. Single blind$.tw.
27. Double blind$.tw.
28. ((treble or triple) adj blind$).tw.
29. placebo$.tw.
30. prospective study/
31. or/12-30
32. case study/
33. case report.tw.
34. abstract report/ or letter/
35. or/32-34
36. 31 not 35
37. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
38. 36 not 37
39. 11 and 38
Appendix 5. CINAHL search strategy
1. (MM “Endometrial Diseases+”)
2. TX (endometr* N5 hyperplas*)
3. TX (endometr* N3 proliferat*)
4. 1 OR 2 OR 3
5. (MM “Metformin”)
6. TX Metformin
7. TX glucophage
8. TX (dimethylbiguanidium or glucovance)
9. 5 OR 6 OR 7 OR 8
10. 4 AND 9
Appendix 6. PubMed search strategy
1. Endometrial Hyperplasia[mh]
2. (endometri* and hyperplas*)[tw]
3. (endometri* and proliferat*)[tw]
4. or/1-3
5. Metformin[mh]
6. metformin[tw]
7. glucophage[tw]
8. (dimethylbiguanidine or dimethylguanylguanidine)[tw]
9. (dimethylbiguanidium or glucovance)[tw]
10. or/5-9
11. 4 and 10
12. randomized controlled trial[ptyp]
13. controlled clinical trial[ptyp]
14. randomized[tw]
15. randomized[tw]
16. placebo[tw]
17. randomly[tw]
18. trial[tw]
19. (crossover or cross-over or cross over)[tw]
20. or/12-20
21. animals[mh] not humans[mh]
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22. 20 not 21
23. 11 and 22
Appendix 7. Google Scholar search strategy
Keywords include: “endometrium”, “endometrial”, “hyperplasia, ”proliferation“, ”metformin“
Appendix 8. ClinicalTrials.gov search strategy
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
Appendix 9. World Health Organization International Trials Registry Platform search strategy
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
Appendix 10. OpenGrey search strategy
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
Appendix 11. LILACS search strategy
(endometrial OR endometrium) AND (hyperplasia OR proliferation) AND (metformin OR glucophage OR dimethylbiguanidine
OR dimethylguanylguanidine OR glucovance OR dimethylbiguanidium)
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